Myosin Therapeutics

About Myosin Therapeutics

Myosin Therapeutics is a privately-held biopharmaceutical company focused on developing novel medications targeting cellular motor proteins to address critical unmet medical needs. Their mission is to create targeted therapies that go beyond symptom relief to directly address the root causes of diseases, particularly in central nervous system and oncology indications.

Products & Services

MT-110:A lead program for substance use disorders, specifically targeting Methamphetamine Use Disorder, a chronic disease affecting over 2 million people in the US with no FDA-approved medications. It involves non-muscle myosin II inhibitors to regulate actin polymerization in dendritic spines.

MT-125:A lead program for oncology, targeting Glioblastoma, a devastating cancer with 200,000 annual diagnoses and a 75% one-year mortality rate. It involves dual inhibitors of NMIIA and NMIIIB to block tumor invasion and proliferation.

Specialties

Molecular motor proteins Central nervous system therapies Oncology therapies Substance use disorder treatments Glioblastoma treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Phase IIB Bridge Award T: - FT: Phase IIB Bridge Award	A: 4500000 MR: - FA: $4.5M FAN: 4500000	D: 2025-08-19 FD: 2025-08-19	1 investors
2	RT: Grant T: - FT: Grant	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2025-04-28 FD: 2025-04-28	1 investors
3	RT: Seed T: - FT: Seed	A: 3000000 MR: - FA: over $3 million FAN: 3000000	D: 2025-02-26 FD: 2025-02-26	6 investors

Phase IIB Bridge Award Latest

2025-08-19

$4.5M

1 investor (Pro only)

Grant 2025-04-28

$3.0M

Seed 2025-02-26

$3.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Courtney A. Miller

PhD

P

Patrick R. Griffin

PhD

T

Theodore Kamenecka

PhD

Recent News